Physician profile
Grace Lee
NPI 1154168979
$6,360.81
in general payments reported to CMS, 2019-2025
18 companies · $5,261 in 2025
The $5,261 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,099 · 2025: $5,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,360.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,952.94 | 2024-2025 | |
| Madrigal Pharmaceuticals | $968.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $698.92 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $554.78 | 2024-2025 | Entyvio |
| Janssen Biotech, INC. | $364.17 | 2024-2025 | Tremfya |
| Axsome Therapeutics, INC. | $283.91 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.00 | 2025 | Xifaxan |
| Novo Nordisk INC | $238.66 | 2025 | Wegovy |
| Lilly USA, LLC | $198.71 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $177.47 | 2025 | Voquezna |
| Cequr Corporation | $163.38 | 2025 | Cequr Simplicity |
| Gilead Sciences, INC. | $124.62 | 2025 | Vemlidy |
| Scpharmaceuticals INC. | $121.91 | 2025 | |
| Genzyme Corporation | $105.59 | 2025 | |
| Exact Sciences Corporation | $59.13 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $46.75 | 2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $23.82 | 2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $16.14 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.